Comparative in vitro activity of garenoxacin against Chlamydia spp.

被引：30

作者：

Donati, M ^{[1
]}

Pollini, GM ^{[1
]}

Sparacino, M ^{[1
]}

Fortugno, MT ^{[1
]}

Laghi, E ^{[1
]}

Cevenini, R ^{[1
]}

机构：

[1] Univ Bologna, Policlin S Orsola Malpighi, DMCSS, Sez Microbiol, I-40138 Bologna, Italy

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2002年 / 50卷 / 03期

关键词：

D O I：

10.1093/jac/dkf145

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The in vitro susceptibilities of 33 isolates of Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci to a new quinolone drug, garenoxacin (BMS-284756), in comparison with levofloxacin, ciprofloxacin, doxycycline, erythromycin and roxithromycin, were determined. Garenoxacin was the most active of the quinolone drugs tested, with identical MIC and MBC, which ranged from 0.007 to 0.03 mg/L. The MIC and MBC of the other two quinolones tested, levofloxacin and ciprofloxacin, were also identical, ranging from 0.25 to 2 mg/L. The MICs and MBCs of doxycycline, erythromycin and roxithromycin were also determined.

引用

页码：407 / 409

页数：3

共 10 条

[1]

CEVENINI R, 1987, FEMS MICROBIOL LETT, V42, P47, DOI 10.1111/j.1574-6968.1987.tb02297.x

[2] Comparative in-vitro activity of levofloxacin against Chlamydia spp. [J].

Donati, M ;

Rumpianesi, F ;

Marchetti, F ;

Sambri, V ;

Cevenini, R .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (05) :670-671

[3] Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. [J].

Donati, M ;

Fermepin, MR ;

Olmo, A ;

D'Apote, L ;

Cevenini, R .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (06) :825-827

[4] Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756 [J].

Fung-Tomc, JC ;

Minassian, B ;

Kolek, B ;

Huczko, E ;

Aleksunes, L ;

Stickle, T ;

Washo, T ;

Gradelski, E ;

Valera, L ;

Bonner, DP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3351-3356

[5] Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci [J].

Jones, RN ;

Pfaller, MA ;

Stilwell, M .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 39 (02) :133-135

[6] In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae [J].

Malay, S ;

Roblin, PM ;

Reznik, T ;

Kutlin, A ;

Hammerschlag, MR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) :517-518

[7] Chlamydiae as pathogens: New species and new issues [J].

Peeling, RW ;

Brunham, RC .

EMERGING INFECTIOUS DISEASES, 1996, 2 (04) :307-319

[8] Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp. [J].

Rhomberg, PR ;

Biedenbach, DJ ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 40 (1-2) :45-49

[9] In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae [J].

Takahata, M ;

Shimakura, M ;

Hori, R ;

Kizawa, K ;

Todo, Y ;

Minami, S ;

Watanabe, Y ;

Narita, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :312-315

[10] In vitro activity of BAY 12-8039, a new fluoroquinolone [J].

Woodcock, JM ;

Andrews, JM ;

Boswell, FJ ;

Brenwald, NP ;

Wise, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :101-106

← 1 →